A different study exploited the Asp133-Glu196 switch in the hinge-binding region between the GSK-3 isozymes to develop selective GSK-3α inhibitors with therapeutic activity in treating AML and FXS [46,47]. This evidence concerns the gene GSK3A and acute myeloid leukemia.